LncRNA TRHDE-AS1 Correlated with Genomic Landscape and Clinical Outcome in Glioma

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2023 May 27

PMID 37239411

Authors

Jinxuan Xie

Yi Lin

Yajie Li

Aizhong Fang

Xin Li

Songlin Wang

Wenbin Li

Affiliations

Soon will be listed here.

Abstract

The role of lncRNA in cancer development has received more and more attention in research. A variety of lncRNAs are associated with the occurrence and development of glioma. However, the role of TRHDE-AS1 in glioma is still unknown. In this study, we explored the role of TRHDE-AS1 in glioma through bioinformatic methods. We first identified an association between TRHDE-AS1 and tumor prognosis in pan-cancer analysis. Subsequently, the expression levels of TRHDE-AS1 in various clinical types of glioma were compared, and significant differences were found in pathological classification, WHO classification, molecular classification, IDH mutation, and age stratification. We analyzed the genes co-expressed with TRHDE-AS1 in glioma. In the functional analysis of TRHDE-AS1, we found that TRHDE-AS1 may be involved in the regulation of synapse-related functions. In glioma cancer driver gene correlation analysis, it was also found that TRHDE-AS1 was significantly correlated with the expression levels of multiple driver genes such as TP53, BRAF, and IDH1. By comparing the mutant profiles of the high and low TRHDE-AS1 groups, we also found that there may be differences in TP53 and CIC gene mutations in low-grade gliomas. Subsequent correlation analysis between TRHDE-AS1 and glioma immune microenvironment showed that the expression level of TRHDE-AS1 was correlated with a variety of immune cells. Therefore, we believe that TRHDE-AS1 is involved in the occurrence and development of glioma and has the ability to predict the prognosis of glioma as a biomarker of glioma.

Citing Articles

expression is associated with lung adenocarcinoma prognosis and immune infiltration and regulates lung adenocarcinoma cell proliferation and metastasis through the MAPK/ERK pathway.

Xu S, Xu Y, Chai W, Liu X, Li J, Sun L J Thorac Dis. 2024; 16(6):3764-3781.

PMID: 38983163 PMC: 11228747. DOI: 10.21037/jtd-24-8.

The pathogenesis mechanism and potential clinical value of lncRNA in gliomas.

Liu Y, Yuan H, Fan J, Wang H, Xie H, Wan J Discov Oncol. 2024; 15(1):266.

PMID: 38967893 PMC: 11226588. DOI: 10.1007/s12672-024-01144-4.

References

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

Panni S, Lovering R, Porras P, Orchard S . Non-coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech. 2019; 1863(6):194417. DOI: 10.1016/j.bbagrm.2019.194417. View

Fan Y, Potdar A, Gong Y, Eswarappa S, Donnola S, Lathia J . Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1α accumulation. Nat Cell Biol. 2014; 16(5):445-56. PMC: 4036069. DOI: 10.1038/ncb2954. View

Wolf D, Harris N, Rotter V . Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell. 1984; 38(1):119-26. DOI: 10.1016/0092-8674(84)90532-4. View

Lu Z, Chen Y, Chen S, Zhu X, Wang C, Wang Z . Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma. Oxid Med Cell Longev. 2022; 2022:1494520. PMC: 9750773. DOI: 10.1155/2022/1494520. View

Smith J, Perry A, Borell T, Lee H, OFallon J, Hosek S . Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18(3):636-45. DOI: 10.1200/JCO.2000.18.3.636. View

Mellinghoff I, Penas-Prado M, Peters K, Burris 3rd H, Maher E, Janku F . Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res. 2021; 27(16):4491-4499. PMC: 8364866. DOI: 10.1158/1078-0432.CCR-21-0611. View

Hu Y, Liu H, Zhu Z, Qi X, Yuan W, Tian M . LACTB suppresses migration and invasion of glioblastoma via downregulating RHOC/Cofilin signaling pathway. Biochem Biophys Res Commun. 2022; 629:17-25. DOI: 10.1016/j.bbrc.2022.09.002. View

Ramaswamy V, Hielscher T, Mack S, Lassaletta A, Lin T, Pajtler K . Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016; 34(21):2468-77. PMC: 4962737. DOI: 10.1200/JCO.2015.65.7825. View

10.

Chen R, Smith-Cohn M, Cohen A, Colman H . Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2017; 14(2):284-297. PMC: 5398991. DOI: 10.1007/s13311-017-0519-x. View

11.

Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T . Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol. 2004; 14(1):34-42. PMC: 8095850. DOI: 10.1111/j.1750-3639.2004.tb00495.x. View

12.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

13.

Geisler S, Coller J . RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013; 14(11):699-712. PMC: 4852478. DOI: 10.1038/nrm3679. View

14.

Yang B, Han Z, Wang W, Ma Y, Chu S . GNG5 is an unfavourable independent prognostic indicator of gliomas. J Cell Mol Med. 2020; 24(21):12873-12878. PMC: 7686969. DOI: 10.1111/jcmm.15923. View

15.

Srivastava S, Zou Z, Pirollo K, Blattner W, Chang E . Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990; 348(6303):747-9. DOI: 10.1038/348747a0. View

16.

Wang P, Zhang J, He S, Xiao B, Peng X . SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas. Cancer Cell Int. 2020; 20(1):573. PMC: 7694905. DOI: 10.1186/s12935-020-01675-0. View

17.

Eliyahu D, Raz A, Gruss P, Givol D, Oren M . Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 1984; 312(5995):646-9. DOI: 10.1038/312646a0. View

18.

Wu Z, Lun P, Ji T, Niu J, Sun X, Liu X . LncRNA SNHG25 Promotes Glioma Progression Through Activating MAPK Signaling. Mol Neurobiol. 2022; 59(11):6993-7005. DOI: 10.1007/s12035-022-03015-x. View

19.

Zhuan B, Lu Y, Chen Q, Zhao X, Li P, Yuan Q . Overexpression of the long noncoding RNA TRHDE-AS1 inhibits the progression of lung cancer via the miRNA-103/KLF4 axis. J Cell Biochem. 2019; 120(10):17616-17624. DOI: 10.1002/jcb.29029. View

20.

Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C . Molecular markers in low-grade gliomas: predictive or prognostic?. Clin Cancer Res. 2011; 17(13):4588-99. DOI: 10.1158/1078-0432.CCR-10-3194. View